Paper10075615
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
Moreland LW and 18 others. Ann Intern Med, 1999. Cited by 1,195 papers, by iCite.
Cite this record
ConductScience Library. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Papers, record 10075615. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/10075615
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Clinical Trial, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Inflammatory Agents, Non-Steroidal | Major topic |
| Arthritis, Rheumatoid | Major topic |
| Immunoglobulin G | Major topic |
| Receptors, Tumor Necrosis Factor | Major topic |
| Algorithms | |
| Dose-Response Relationship, Drug | |
| Double-Blind Method | |
| Drug Administration Schedule | |
| Etanercept | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Patient Dropouts | |
| Quality of Life | |
| Recombinant Proteins | |
| Statistics as Topic |
Source PubMed
Cited by343
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,195 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42864407 | Computational design and translational development of TCR-mimic scFv antibodies for peptide-HLA neoantigen targeting. | NPJ Drug Discov | 2026 | https://conductscience.org/library/papers/42864407 | PubMed |
| 42104019 | De novo and scaffold-based design of GDF15 binders for cancer cachexia diagnostics and therapeutics. | Exp Mol Med | 2026 | https://conductscience.org/library/papers/42104019 | PubMed |
| 41733787 | Role of macrophages and dendritic cells in autoimmune diseases: a specific focus on tumor necrosis factor targeting therapies against rheumatoid arthritis. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/41733787 | PubMed |
| 40836173 | Transforming rheumatoid arthritis care: dynamic budget impact models with ACR to DAS28 mapping for anti-TNFs, JAK inhibitors, and interleukins. | Clin Rheumatol | 2025 | https://conductscience.org/library/papers/40836173 | PubMed |
| 40091354 | Anti-Rheumatic potential of biological DMARDS and protagonistic role of bio-markers in early detection and management of rheumatoid arthritis. | Innate Immun | 2025 | https://conductscience.org/library/papers/40091354 | PubMed |
| 39802551 | Chinese guidelines for the diagnosis and treatment of rheumatoid arthritis: 2024 update. | Rheumatol Immunol Res | 2024 | https://conductscience.org/library/papers/39802551 | PubMed |
| 38827788 | Different modalities to manage rheumatoid arthritis: an A to Z story. | Future Sci OA | 2024 | https://conductscience.org/library/papers/38827788 | PubMed |
| 38479734 | Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA. | BMJ Open | 2024 | https://conductscience.org/library/papers/38479734 | PubMed |
| 37371813 | Risk Factors of Ixekizumab-Induced Injection Site Reactions in Patients with Psoriatic Diseases: Report from a Single Medical Center. | Biomedicines | 2023 | https://conductscience.org/library/papers/37371813 | PubMed |
| 36836166 | Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy. | J Clin Med | 2023 | https://conductscience.org/library/papers/36836166 | PubMed |
| 36497082 | The Role of Bone Morphogenetic Protein Receptor Type 2 (BMPR2) and the Prospects of Utilizing Induced Pluripotent Stem Cells (iPSCs) in Pulmonary Arterial Hypertension Disease Modeling. | Cells | 2022 | https://conductscience.org/library/papers/36497082 | PubMed |
| 36355537 | A Review of the Safety of Interleukin-17A Inhibitor Secukinumab. | Pharmaceuticals (Basel) | 2022 | https://conductscience.org/library/papers/36355537 | PubMed |
| 35322865 | Piceatannol suppresses inflammation and promotes apoptosis in rheumatoid arthritis‑fibroblast‑like synoviocytes by inhibiting the NF‑κB and MAPK signaling pathways. | Mol Med Rep | 2022 | https://conductscience.org/library/papers/35322865 | PubMed |
| 35003068 | Toward Overcoming Treatment Failure in Rheumatoid Arthritis. | Front Immunol | 2021 | https://conductscience.org/library/papers/35003068 | PubMed |
| 34429666 | Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension. | J Exp Pharmacol | 2021 | https://conductscience.org/library/papers/34429666 | PubMed |
| 34148193 | A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study. | Rheumatol Ther | 2021 | https://conductscience.org/library/papers/34148193 | PubMed |
| 33800290 | The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33800290 | PubMed |
| 33569512 | Therapeutic potential of TNFα inhibitors in chronic inflammatory disorders: Past and future. | Genes Dis | 2021 | https://conductscience.org/library/papers/33569512 | PubMed |
| 33441191 | Long-term remission and biologic persistence rates: 12-year real-world data. | Arthritis Res Ther | 2021 | https://conductscience.org/library/papers/33441191 | PubMed |
| 33399862 | Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus. | Cardiovasc Res | 2021 | https://conductscience.org/library/papers/33399862 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/10075615
GET https://conductscience.org/api/papers/v1/10075615/cited_by?page=2